Scott Lish Sells 16,666 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Key Points

• Scott Lish, COO of Alphatec Holdings, sold 16,666 shares of the company's stock for approximately $249,990, which decreased his ownership stake by 2.41%.
• Alphatec's stock currently trades at $15.34, reflecting a 3.2% increase and a significant rise from its one-year low of $4.88.
• The company reported a 27.5% increase in revenue year-over-year, achieving $185.54 million for the last quarter, which exceeded analysts' expectations.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 16,666 shares of the company's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total transaction of $249,990.00. Following the transaction, the chief operating officer owned 674,332 shares of the company's stock, valued at $10,114,980. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Scott Lish also recently made the following trade(s):

• On Monday, August 4th, Scott Lish sold 17,857 shares of Alphatec stock. The shares were sold at an average price of $14.00, for a total value of $249,998.00.
• On Friday, August 1st, Scott Lish sold 36,081 shares of Alphatec stock. The shares were sold at an average price of $12.53, for a total transaction of $452,094.93.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total transaction of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The stock was sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total transaction of $719,875.00.

Alphatec Trading Up 0.5%

Shares of Alphatec stock traded up $0.07 on Friday, hitting $14.97. The stock had a trading volume of 1,745,343 shares, compared to its average volume of 2,816,030. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $15.46. The stock's 50-day simple moving average is $11.63 and its two-hundred day simple moving average is $11.28. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -13.25 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter last year, the business posted ($0.29) EPS. The business's revenue was up 27.5% on a year-over-year basis. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Nuveen LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at about $135,874,000. Vanguard Group Inc. raised its holdings in shares of Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock valued at $60,990,000 after purchasing an additional 45,792 shares during the last quarter. American Century Companies Inc. lifted its position in Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company's stock valued at $59,117,000 after purchasing an additional 840,974 shares during the period. Royal Bank of Canada boosted its holdings in Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock worth $35,773,000 after purchasing an additional 342,656 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Alphatec by 7.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company's stock valued at $29,946,000 after purchasing an additional 185,297 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ATEC. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a report on Saturday. Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.